Publicacions destacades

• Detection of cell-free circulating BRAFV 600E by droplet digital PCR in melanoma and non-melanoma patients under dermatological surveillance

  Autors: Calbet-Llopart N, Potrony M, Tell-Martí G, Carrera C, Barreiro A, Aguilera P, Podlipnik S, Puig S, Malvehy J, Puig-Butillé JA.

  Referència: British Journal Of Dermatology 2020; 182(2):382-389.

• Inherited MC1R variants in melanoma patients are associated with better survival in females

  Autors: Lira FE, Podlipnik S, Potrony M, Tell-Martí G, Calbet-Llopart N, Barreiro A, Carrera C, Malvehy J, Puig S.

  Referència: British Journal Of Dermatology 2020; 182(1):138-146.

• POT1 germline mutations but not TERT promoter mutations are implicated in melanoma susceptibility in a large cohort of Spanish melanoma families

  Autors: Potrony M, Puig-Butille JA, Ribera-Sola M, Iyer V, Robles-Espinoza CD, Aguilera P, Carrera C, Malvehy J, Badenas C, Landi MT, Adams DJ, Puig S.

  Referència: British Journal Of Dermatology 2019; 181(1):105-113.

• Cost-effectiveness analysis of imaging strategy for an intensive follow-up of patients with AJCC stage IIB, IIC and III malignant melanoma.

  Autors: Podlipnik S, Moreno-Ramírez D, Carrera C, Barreiro A, Manubens E, Ferrandiz-Pulido L, Sánchez M, Vidal-Sicart S, Malvehy J, Puig S.

  Referència: British Journal Of Dermatology 2019; 180(5):1190-1197.

• Early outcome of a 31-gene expression profile test in 86 AJCC stage IB-II melanoma patients

  Autors: Podlipnik S, Carrera C, Boada A, Richarz NA, López-Estebaranz JL, Pinedo-Moraleda F, Elosua-González M, Martín-González MM, Carrillo-Gijón R, Redondo P, Moreno E, Malvehy J, Puig S.

  Referència: Journal Of The European Academy Of Dermatology And Venereology 2019; 33(5):857-862.

• Genetic Abnormalities in Large to Giant Congenital Nevi: Beyond NRAS mutations

  Autors: Martins da Silva V, Martinez-Barrios E, Tell-Martí G, Dabad M, Carrera C, Aguilera P, Brualla D, Esteve-Codina A, Vicente A, Puig S, Puig-Butillé JA, Malvehy J.

  Referència: Journal Of Investigative Dermatology 2019; 139(4):900-908.

• Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.

  Autors: Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Lichinitser M, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Maio M, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan P, Ibrahim N, Marreaud S, van Akkooi ACJ, Suciu S, Robert C.

  Referència: New England Journal Of Medicine 2018; 378(19):1789-1801.

• Melanocortin 1 receptor (MC1R) polymorphisms' influence on size and dermoscopic features of nevi.

  Autors: Vallone MG, Tell-Marti G, Potrony M, Rebollo-Morell A, Badenas C, Puig-Butille JA, Gimenez-Xavier P, Carrera C, Malvehy J, Puig S.

  Referència: Pigment Cell & Melanoma Research 2018; 31(1):39-50.

• Performance of diagnostic tests in an intensive follow-up protocol for patients with American Joint Committee on Cancer (AJCC) stage IIB, IIC, and III localized primary melanoma: A prospective cohort study

  Autors: Podlipnik S, Carrera C, Sánchez M, Arguis P, Olondo ML, Vilana R, Rull R, Vidal-Sicart S, Vilalta A, Conill C, Malvehy J, Puig S.

  Referència: Journal Of The American Academy Of Dermatology 2016; 75(3):516-524.

• Characterization of individuals at high risk of developing melanoma in Latin America: bases for genetic counseling in melanoma

  Autors: Puig S, Potrony M, Cuellar F, Puig-Butille JA, Carrera C, Aguilera P, Nagore E, Garcia-Casado Z, Requena C, Kumar R, Landman G, Costa Soares de Sá B, Gargantini Rezze G, Facure L, de Avila AL, Achatz MI, Carraro DM, Duprat Neto JP, Grazziotin TC, Bonamigo RR, Rey MC, Balestrini C, Morales E, Molgo M, Bakos RM, Ashton-Prolla P, Giugliani R, Larre Borges A, Barquet V, Pérez J, Martínez M, Cabo H, Cohen Sabban E, Latorre C, Carlos-Ortega B, Salas-Alanis JC, Gonzalez R, Olazaran Z, Malvehy J, Badenas C.

  Referència: Genetics In Medicine 2016; 18(7):727-736.